The webinar will feature a presentation by Key Opinion Leader (KOL) Scott Kopetz, M.D., Ph.D., (MD Anderson Cancer Center) who will provide an overview of unmet medical needs and therapeutic opportunities in cancers driven by the RAS/MAPK pathway, with a particular focus in gastrointestinal (GI) cancers.

Erasca will provide an overview of the company’s pipeline and discuss its clinical development strategy targeting the RAS/MAPK pathway for the treatment of non-small cell lung cancer, GI cancers, and hematologic malignancies. Erasca will highlight the data within its 2022 AACR poster presentations that support its robust clinical development plan.

A live question and answer session will follow.